Content
Executive summary
Data sources
Accounts
Novel agents in late stage clinical development
Definitions of terms
1: Abbott Laboratories
Corporate structure
Us operations
International operations (excluding us)
Global businesses
Geographic breakdown
Human pharmaceuticals
Anti-infectives
Cns disorders
Urology
Cardiovascular
Hospital and ross product lines
Commercial collaborations
Research & development
Corporate and financial data
2: American Home Products
Corporate structure
Geographic breakdown
Human pharmaceuticals
Women's health
Consumer health
Neurosciences
Rheumatology
Anti-infectives
Other product lines
Commercial collaborations
Research & development
Corporate and financial data
3: Amgen Incorporated
Corporate structure and geographic breakdown
Human pharmaceuticals
Commercial collaborations
Research & development
Corporate and financial data
4: Bristol-Myers Squibb
Corporate structure
Geographic breakdown
Human pharmaceuticals
Cardiovascular
Oncology
Anti-infectives
Diabetes
Central nervous system
Consumer medicines
Commercial collaborations
Research & development
Corporate and financial data
5: Johnson & Johnson
Corporate structure
Geographic breakdown
Human pharmaceuticals
Haematology
Cns (products)
Anti-infectives
Gastro-intestinal
Other major therapy areas
Commercial collaborations
Research & development
Corporate and financial data
6: Eli Lilly & Company
Corporate structure and geographic breakdown
Human pharmaceuticals
Neurosciences
Endocrinology
Anti-infectives
Cardiovascular
Oncology
Commercial collaborations
Research & development
Corporate and financial data
7: Merck & Co
Corporate structure
Geographic breakdown
Human pharmaceuticals
Anti-infectives
Anti-inflammatories
Anti-ulcerants
Cardiovasculars
Ophthalmology
Osteoporosis
Respiratory
Other therapy areas
Commercial collaborations
Research & development
Corporate and financial data
8: Pfizer Incorporated
9: Pfizer Incorporated
Corporate structure
Geographic breakdown
Human pharmaceuticals
Cardiovasculars
Infectious disease
Cns products
Erectile dysfunction
Arthritis
Allergy
Consumer health
Commercial collaborations
Research & development
Corporate and financial data
10: Warner Lambert Company
Corporate structure
Geographic breakdown
Human pharmaceuticals
Cardiovasculars
Cns disorders
Anti-infectives
Diabetes
Consumer health
Other product lines
Commercial collaborations
Research & development
Corporate and financial data
11: Pharmacia Corporation
12: Monsanto Company
Corporate structure
Geographic breakdown
Human pharmaceuticals
Commercial collaborations
Research & development
Corporate and financial data
13: Pharmacia & Upjohn Incorporated
Corporate structure
Geographic breakdown
Human pharmaceuticals
Women's health
Urology
Metabolic diseases
Oncology
Ophthalmology
Cns disorders
Consumer health care
Other product lines
Commercial collaborations
Research & development
Corporate and financial data
14: Schering-Plough Corporation
Corporate structure
Geographic breakdown
Human pharmaceuticals
Allergy and respiratory products
Anti-infectives and oncology
Dermatologicals
Cardiovasculars
Otc product lines
Commercial collaborations
Research & development
Corporate and financial data
15: Tap
Research & development
Corporate and financial data
List of Tables
Table 1: US-domiciled pharmaceutical companies - sales performance (1999)
Table 2: US-domiciled pharmaceutical companies - domestic sales (1999)
Table 3: US-domiciled pharmaceutical companies - pharmaceutical r&d expenditure (1999)
Table 4: US-domiciled pharmaceutical companies
Abbott Laboratories
Table 1.1: Business segment analysis (year end 31 december 1999)
Table 1.2: Geographical sales analysis
Table 1.3: Human pharmaceuticals major product performance (1999)
Table 1.4: Major commercial agreements
Table 1.5: Novel agents in late stage clinical development
Table 1.6: Financial data
American Home Products
Table 2.1: Business segment analysis (year end 31 december 1999)
Table 2.2: Geographical sales analysis
Table 2.3: Human pharmaceuticals - major product performance (1999)
Table 2.4: Major commercial agreements
Table 2.5: Novel agents in late stage clinical development
Table 2.6: Financial data
Amgen Incorporated
Table 3.1: Human pharmaceuticals product performance in 1999
Table 3.2: Novel agents in late stage clinical development
Table 3.3: Financial data
Bristol-Myers Squibb
Table 4.1: Business segment analysis (year end 31 december 1999)
Table 4.2: Geographical sales analysis
Table 4.3: Human pharmaceuticals - major product performance (1999)
Table 4.4: Major commercial agreements
Table 4.5: Novel agents in late stage clinical development
Table 4.6: Financial data
Johnson & Johnson
Table 5.1: Business segment analysis (year end 31 december 1999)
Table 5.2: Geographical sales analysis
Table 5.3: Human pharmaceuticals - major product performance (1999)
Table 5.4: Major commercial agreements
Table 5.5: Novel agents in late stage clinical development
Table 5.6: Financial data
Eli Lilly & Company
Table 6.1: Business segment analysis (year end 31 december 1999)
Table 6.2: Geographical sales analysis
Table 6.3: Therapy area sales analysis
Table 6.4: Human pharmaceuticals - major product performance (1999)
Table 6.5: Major commercial agreements
Table 6.6: Novel agents in late stage clinical development
Table 6.7: Financial data
Merck & Co
Table 7.1: Business segment analysis (year end 31 december 1999)
Table 7.2: Geographical sales analysis (1999)
Table 7.3: Major therapy area sales
Table 7.4: Human pharmaceuticals - major product performance (1999)
Table 7.5: Novel agents in late stage clinical development
Table 7.6: Financial data (1999)
Pfizer Incorporated
Table 8.1: Business segment analysis (year end 31 december 1999)
Table 8.2: Human pharmaceuticals - major product performance (1999)
Table 8.3: Novel agents in late stage clinical development
Table 8.4: Combined financial data
Pfizer Incorporated
Table 9.1: Business segment analysis (year end 31 december 1999)
Table 9.2: Geographical sales analysis
Table 9.3: Major therapy area sales
Table 9.4: Human pharmaceuticals - major product performance (1999)
Table 9.5: Major commercial agreements
Table 9.6: Novel agents in late stage clinical development
Table 9.7: Financial data
Warner Lambert Company
Table 10.1: Business segment analysis (year end 31 december 1999)
Table 10.2: Human pharmaceuticals - major product performance
Table 10.3: Major commercial agreements
Table 10.4: Novel agents in late stage clinical development
Table 10.5: Financial data
Pharmacia Corporation
Table 11.1: Business segment analysis (year end 31 december 1999)
Table 11.2: Human pharmaceuticals - major product performance (1999)
Table 11.3: Novel agents in late stage clinical development
Table 11.4: Combined financial data
Monsanto Company
Table 12.1: Business segment analysis (year end 31 december 1999) -continuing operations
Table 12.2: Geographical sales analysis (1999)
Table 12.3: Human pharmaceuticals - major product performance (1999)
Table 12.4: Major commercial agreements
Table 12.5: Novel agents in late stage clinical development
Table 12.6: Financial data - continuing operations
Pharmacia & Upjohn Incorporated
Table 13.1: Business segment analysis (year end 31 december 1999)
Table 13.2: Geographical sales analysis
Table 13.3: Human pharmaceuticals - major product performance (1999)
Table 13.4: Major commercial agreements
Table 13.5: Novel agents in late stage clinical development
Table 13.6: Financial data
Schering-Plough Corporation
Table 14.1: Business segment analysis (year end 31 december 1999)
Table 14.2: Geographical sales analysis
Table 14.3: Therapy area sales analysis
Table 14.4: Human pharmaceuticals - major product performance (1999)
Table 14.5: Major commercial agreements
Table 14.6: Novel agents in late stage clinical development
Table 14.7: Financial data
Tap
Table 15.1: Novel agents in late stage clinical development
Table 15.2: Financial data
|
TABLE OF CONTENTS
